FDA Updates Warning Labels On Blockbuster Drugs

Law360, New York (September 20, 2007, 12:00 AM EDT) -- The U.S. Food and Drug Administration announced the findings of its first post-marketing review of of Novartis AG's Exjade, used to treat chronic iron overload in patients receiving regular blood transfusions, saying that the drug could pose serious risks of side effects.

The announcement was part of the agency's first drug safety newsletter, which also contained information about the side effects of several other drugs, including Provigil. Cephalon Corp., Provigil's manufacturer, announced on Monday that it had updated the drug's label to include new warnings....
To view the full article, register now.